Actively Recruiting
A Prospective Registry and Tumor Sample Collection for Patients with T-cell and NK-cell Lymphomas
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-20
1000
Participants Needed
26
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting detailed information in a registry to better understand various types of mature T-cell and natural killer NK-cell lymphomas. This observational study aims to improve knowledge about these rare blood cancers by creating a comprehensive database that includes clinical information and tumor samples from participants. The study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on multiple specific T-cell lymphoma subtypes as defined by recognized classification guidelines. Participants with confirmed mature T-cell or NK-cell lymphoma may choose to provide optional blood and nail samples for future research and biobanking. The study does not involve experimental treatments but gathers data prospectively from individuals meeting strict diagnostic criteria, including those receiving systemic therapy for certain cutaneous lymphoma types. This approach supports long-term data collection rather than testing new therapies. During the study, participants will have clinical data and tumor specimens collected and recorded. Researchers will track the number of participants contributing to the T-cell Lymphoma Master Repository over a 10-year period. The study involves ongoing follow-up to measure disease status and treatment response, with no direct intervention required. Participation helps build a resource to advance future research and understanding of these lymphomas.
CONDITIONS
Brief Title
A Registry for People With T-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written informed consent
- Have an adequate fresh or archival tumor biopsy or plan to obtain one
- Diagnosed with a mature T-cell or natural killer (NK)-cell lymphoma matching recognized criteria, including types such as T-cell prolymphocytic leukemia, aggressive NK-cell leukemia, adult T-cell leukemia/lymphoma, mycosis fungoides (stage IB or higher and receiving active therapy), Sézary syndrome, and others listed
- For mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, or primary cutaneous acral CD8+ T-cell lymphoma, must be receiving systemic therapy
You will not qualify if you...
- Diagnosed with mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, or primary cutaneous acral CD8+ T-cell lymphoma but not receiving systemic therapy
- Unable to provide prospective data, measure response, or complete follow-up assessments as judged by the treating physician
- Patients already in clinical trials may still participate, and participation here does not exclude other trials or vice versa without physician judgment
Research Team
S
Steven Horwitz, MD
A
Alison Moskowitz, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here